Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, LENZ Therapeutics Inc’s stock clocked out at $30.64, down -0.55% from its previous closing price of $30.81. In other words, the price has decreased by -$0.55 from its previous closing price. On the day, 0.82 million shares were traded. LENZ stock price reached its highest trading level at $31.15 during the session, while it also had its lowest trading level at $29.8.
Ratios:
To gain a deeper understanding of LENZ’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.54 and its Current Ratio is at 20.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 30 ’25 when Versant Venture Capital VI, L. sold 132,944 shares for $46.01 per share. The transaction valued at 6,117,323 led to the insider holds 1,050,599 shares of the business.
Versant Venture Capital VI, L. sold 92,030 shares of LENZ for $4,234,695 on Sep 30 ’25. The 10% Owner now owns 764,127 shares after completing the transaction at $46.01 per share. On Sep 18 ’25, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 90,654 shares for $42.23 each. As a result, the insider received 3,828,632 and left with 1,183,543 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 927495168 and an Enterprise Value of 665449024. For the stock, the TTM Price-to-Sale (P/S) ratio is 174.78 while its Price-to-Book (P/B) ratio in mrq is 4.23. Its current Enterprise Value per Revenue stands at 133.09 whereas that against EBITDA is -10.756.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.52, which has changed by 0.13649857 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $50.40, while it has fallen to a 52-week low of $16.53. The 50-Day Moving Average of the stock is -23.70%, while the 200-Day Moving Average is calculated to be -0.57%.
Shares Statistics:
It appears that LENZ traded 767.27K shares on average per day over the past three months and 1197670 shares per day over the past ten days. A total of 28.50M shares are outstanding, with a floating share count of 24.40M. Insiders hold about 14.45% of the company’s shares, while institutions hold 92.49% stake in the company. Shares short for LENZ as of 1760486400 were 5656845 with a Short Ratio of 7.37, compared to 1757894400 on 5020705. Therefore, it implies a Short% of Shares Outstanding of 5656845 and a Short% of Float of 32.98.
Earnings Estimates
The stock of LENZ Therapeutics Inc (LENZ) is currently drawing attention from 6.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.8, with high estimates of -$0.63 and low estimates of -$0.96.
Analysts are recommending an EPS of between -$2.15 and -$2.75 for the fiscal current year, implying an average EPS of -$2.56. EPS for the following year is -$2.5, with 7.0 analysts recommending between -$1.75 and -$3.65.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $49.74M in the next fiscal year. The high estimate is $60.28M and the low estimate is $41.2M.
